ALSUnngled No 36:Accillion

IF 2.5 4区 医学 Q2 CLINICAL NEUROLOGY Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Pub Date : 2017-01-02 DOI:10.1080/21678421.2016.1215400
R. Bedlack, E. Fixsen, C. Quinn, C. Karam, A. Sherman, L. Ostrow, O. Hardiman, T. Heiman-Patterson, L. Gutmann, M. Bromberg, Gregory T. Carter, E. Kabashi, T. Bertorini, T. Mozaffar, P. Andersen, Josep Gamez, M. Dimachkie, Yunxia Wang, P. Wicks, J. Heywood, Steven P Novella, L. Rowland, E. Pioro, Lisa Kinsley, K. Mitchell, J. Glass, S. Sathornsumetee, J. Baker, N. Atassi, D. Forshew, J. Ravits, R. Conwit, C. Jackson, Kate Dalton, K. Tindall, Ginna Gonzalez, J. Robertson, Larry Phillips, M. Benatar, E. Sorenson, C. Shoesmith, S. Nash, N. Maragakis, D. Moore, J. Caress, K. Boylan, C. Armon, M. Grosso, B. Gerecke, J. Wymer, B. Oskarsson, R. Bowser, V. Drory, J. Shefner, N. Lechtzin, Melanie L Leitner, Robert G. Miller, T. Levine, J. Russell, K. Sharma, D. Saperstein, L. McClusky, D. Macgowan, J. Licht, A. Verma, M. Strong, C. Lomen‐Hoerth, R. Tandan, Michael H. Rivner, S. Kolb, M. Polak, S. Rudnicki, Pamela Kittrell, Muddasir Quereshi, G. Sachs, G. Pattee, M. Weiss, J. Kissel, Jonathan M. Goldstein, J. Roths
{"title":"ALSUnngled No 36:Accillion","authors":"R. Bedlack, E. Fixsen, C. Quinn, C. Karam, A. Sherman, L. Ostrow, O. Hardiman, T. Heiman-Patterson, L. Gutmann, M. Bromberg, Gregory T. Carter, E. Kabashi, T. Bertorini, T. Mozaffar, P. Andersen, Josep Gamez, M. Dimachkie, Yunxia Wang, P. Wicks, J. Heywood, Steven P Novella, L. Rowland, E. Pioro, Lisa Kinsley, K. Mitchell, J. Glass, S. Sathornsumetee, J. Baker, N. Atassi, D. Forshew, J. Ravits, R. Conwit, C. Jackson, Kate Dalton, K. Tindall, Ginna Gonzalez, J. Robertson, Larry Phillips, M. Benatar, E. Sorenson, C. Shoesmith, S. Nash, N. Maragakis, D. Moore, J. Caress, K. Boylan, C. Armon, M. Grosso, B. Gerecke, J. Wymer, B. Oskarsson, R. Bowser, V. Drory, J. Shefner, N. Lechtzin, Melanie L Leitner, Robert G. Miller, T. Levine, J. Russell, K. Sharma, D. Saperstein, L. McClusky, D. Macgowan, J. Licht, A. Verma, M. Strong, C. Lomen‐Hoerth, R. Tandan, Michael H. Rivner, S. Kolb, M. Polak, S. Rudnicki, Pamela Kittrell, Muddasir Quereshi, G. Sachs, G. Pattee, M. Weiss, J. Kissel, Jonathan M. Goldstein, J. Roths","doi":"10.1080/21678421.2016.1215400","DOIUrl":null,"url":null,"abstract":"Accilion is a topical mineral cream advertised by Advanced Mineral Compounds, LLC (AMC, 2). It is one of several products with different names and websites (Table I) that trace their origin to a botanist named John Wayne Kennedy (20) and his patent entitled ‘Bioavailable minerals for plant health’ (19). Three of these products are topical mineral creams while a fourth is a mineral supplement marketed to be sprayed on agricultural crops to promote disease resistance and improve growth. These products appear to have similar ingredients and similar proposed mechanisms, and nearly identical description by which they claim to distinguish themselves from other mineral compounds (Table I). A representative from AMC has told us that these products are different in important ways including ‘‘zinc/copper ratios’’ and ‘‘redox’’, that there is a legal dispute underway between the current owners, and that ‘‘efforts to have these compounds independently assessed and thoroughly verified are now routinely obstructed’’ (21). Interestingly, the same cancer-patient testimonials appear for three of these products and the same ALS-patient testimonial appears for two of them (Table I).","PeriodicalId":7740,"journal":{"name":"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2017-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/21678421.2016.1215400","citationCount":"1","resultStr":"{\"title\":\"ALSUntangled No. 36: Accilion\",\"authors\":\"R. Bedlack, E. Fixsen, C. Quinn, C. Karam, A. Sherman, L. Ostrow, O. Hardiman, T. Heiman-Patterson, L. Gutmann, M. Bromberg, Gregory T. Carter, E. Kabashi, T. Bertorini, T. Mozaffar, P. Andersen, Josep Gamez, M. Dimachkie, Yunxia Wang, P. Wicks, J. Heywood, Steven P Novella, L. Rowland, E. Pioro, Lisa Kinsley, K. Mitchell, J. Glass, S. Sathornsumetee, J. Baker, N. Atassi, D. Forshew, J. Ravits, R. Conwit, C. Jackson, Kate Dalton, K. Tindall, Ginna Gonzalez, J. Robertson, Larry Phillips, M. Benatar, E. Sorenson, C. Shoesmith, S. Nash, N. Maragakis, D. Moore, J. Caress, K. Boylan, C. Armon, M. Grosso, B. Gerecke, J. Wymer, B. Oskarsson, R. Bowser, V. Drory, J. Shefner, N. Lechtzin, Melanie L Leitner, Robert G. Miller, T. Levine, J. Russell, K. Sharma, D. Saperstein, L. McClusky, D. Macgowan, J. Licht, A. Verma, M. Strong, C. Lomen‐Hoerth, R. Tandan, Michael H. Rivner, S. Kolb, M. Polak, S. Rudnicki, Pamela Kittrell, Muddasir Quereshi, G. Sachs, G. Pattee, M. Weiss, J. Kissel, Jonathan M. Goldstein, J. Roths\",\"doi\":\"10.1080/21678421.2016.1215400\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Accilion is a topical mineral cream advertised by Advanced Mineral Compounds, LLC (AMC, 2). It is one of several products with different names and websites (Table I) that trace their origin to a botanist named John Wayne Kennedy (20) and his patent entitled ‘Bioavailable minerals for plant health’ (19). Three of these products are topical mineral creams while a fourth is a mineral supplement marketed to be sprayed on agricultural crops to promote disease resistance and improve growth. These products appear to have similar ingredients and similar proposed mechanisms, and nearly identical description by which they claim to distinguish themselves from other mineral compounds (Table I). A representative from AMC has told us that these products are different in important ways including ‘‘zinc/copper ratios’’ and ‘‘redox’’, that there is a legal dispute underway between the current owners, and that ‘‘efforts to have these compounds independently assessed and thoroughly verified are now routinely obstructed’’ (21). Interestingly, the same cancer-patient testimonials appear for three of these products and the same ALS-patient testimonial appears for two of them (Table I).\",\"PeriodicalId\":7740,\"journal\":{\"name\":\"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2017-01-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1080/21678421.2016.1215400\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/21678421.2016.1215400\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21678421.2016.1215400","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 1

摘要

Accilion是一种由Advanced mineral Compounds, LLC (AMC, 2)宣传的局部矿物质霜。它是几种名称和网站不同的产品之一(表1),其起源可追溯到一位名叫John Wayne Kennedy(20)的植物学家,他的专利名为“植物健康的生物可利用矿物质”(19)。其中三种产品是外用矿物面霜,第四种是一种矿物质补充剂,用于喷洒在农作物上,以增强抗病性和促进生长。这些产品似乎具有相似的成分和相似的建议机制,并且几乎相同的描述,他们声称将自己与其他矿物质化合物区分开来(表1)。AMC的代表告诉我们,这些产品在重要方面不同,包括“锌/铜比例”和“氧化还原”,目前的所有者之间正在进行法律纠纷。而且“对这些化合物进行独立评估和彻底验证的努力现在经常受到阻碍”(21)。有趣的是,这些产品中的三种出现了相同的癌症患者推荐,其中两种出现了相同的als患者推荐(表1)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
ALSUntangled No. 36: Accilion
Accilion is a topical mineral cream advertised by Advanced Mineral Compounds, LLC (AMC, 2). It is one of several products with different names and websites (Table I) that trace their origin to a botanist named John Wayne Kennedy (20) and his patent entitled ‘Bioavailable minerals for plant health’ (19). Three of these products are topical mineral creams while a fourth is a mineral supplement marketed to be sprayed on agricultural crops to promote disease resistance and improve growth. These products appear to have similar ingredients and similar proposed mechanisms, and nearly identical description by which they claim to distinguish themselves from other mineral compounds (Table I). A representative from AMC has told us that these products are different in important ways including ‘‘zinc/copper ratios’’ and ‘‘redox’’, that there is a legal dispute underway between the current owners, and that ‘‘efforts to have these compounds independently assessed and thoroughly verified are now routinely obstructed’’ (21). Interestingly, the same cancer-patient testimonials appear for three of these products and the same ALS-patient testimonial appears for two of them (Table I).
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.40
自引率
10.70%
发文量
64
期刊介绍: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration is an exciting new initiative. It represents a timely expansion of the journal Amyotrophic Lateral Sclerosis in response to the clinical, imaging pathological and genetic overlap between ALS and frontotemporal dementia. The expanded journal provides outstanding coverage of research in a wide range of issues related to motor neuron diseases, especially ALS (Lou Gehrig’s disease) and cognitive decline associated with frontotemporal degeneration. The journal also covers related disorders of the neuroaxis when relevant to these core conditions.
期刊最新文献
The correlation between social support, coping style, advance care planning readiness, and quality of life in patients with amyotrophic lateral sclerosis: a cross-sectional study. Effects of COVID-19 on motor neuron disease mortality in the United States: a population-based cross-sectional study SOD1 gene screening in ALS – frequency of mutations, patients’ attitudes to genetic information and transition to tofersen treatment in a multi-center program How to break the news in amyotrophic lateral sclerosis/motor neuron disease: practical guidelines from experts A nurse coaching intervention to improve support to individuals living with ALS.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1